VYGR Live signaler | Maksimer profitt med Getagraph.com

SELG 116224 min ago

@ $7.28

Utstedt: 14 feb 2024 @ 15:30

Avkastning: 21.02%

Forrige signal: feb 13 - 15:30

Forrige signal: Kjøp

Avkastning: -1.38 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	453 367
Gjennomsnittsvolum	658 990
Markedsverdi	478.39M
EPS	$0 ( 2024-02-28 )
Neste inntjeningsdato	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.97
ATR14	$0.0130 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferguson Toby	Buy	105 000	Common Stock
2024-04-02	Swartz Robin	Sell	1 357	Common Stock
2024-04-02	Sandrock Alfred	Sell	12 115	Common Stock
2024-03-25	Ferguson Toby	Buy	210 000	Stock Option (Right to Buy)
2024-03-25	Ferguson Toby	Buy	0

INSIDER POWER
44.64
Last 94 transactions
Buy: 7 546 876 \| Sell: 3 757 926

Volum Korrelasjon

Lang: 0.00 (neutral)

Kort: 0.06 (neutral)

Signal:(55.939) Neutral

Voyager Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
DYNT	0.929
DGLY	0.909
CRNC	0.909
ATNX	0.905
GFAI	0.905
LIVE	0.897
FTFT	0.896
ECOR	0.896
CFRX	0.889
APRE	0.886

10 Mest negative korrelasjoner
MTEX	-0.862
ZENV	-0.859
VERA	-0.852
GRIN	-0.848
GRPH	-0.843
DSPC	-0.835
JAN	-0.832
RIVN	-0.831
LAWS	-0.827
VERX	-0.826

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Voyager Therapeutics Inc Korrelasjon - Valuta/Råvare

0.25
( neutral )

0.44
( neutral )

0.00
( neutral )

0.28
( neutral )

0.07
( neutral )

Voyager Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$250.01M
Bruttogevinst:	$245.57M (98.22 %)
EPS:	$3.08

FY	2023
Omsetning:	$250.01M
Bruttogevinst:	$245.57M (98.22 %)
EPS:	$3.08

FY	2022
Omsetning:	$40.91M
Bruttogevinst:	$34.72M (84.87 %)
EPS:	$-1.210

FY	2021
Omsetning:	$37.42M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.